Cleveland Clinic spinoff company to start clinical trials for Alzheimer’s disease
The U.S. Food and Drug Administration gave the company the go-ahead to begin its first in-human studies of the drug, NTRX-07, in an ascending dose study schedule to begin midsummer.
NeuroTherapia plans to follow this study, which will be in healthy volunteers, with another study in patients with Alzheimer’s disease to explore the safety of repeated dosing of NTRX-07 and to look for changes in inflammation, according to the release.
NTRX-07, a small orally available molecule, targets receptors that increase in diseases, including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and chronic pain syndromes, according to the release.
Naguib and Foss are entitled to a portion of any revenues Cleveland Clinic receives related to the technology, according to the release. Specific terms of the revenue share were not disclosed.